Clinical Trial

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Study acronym: COLUMBUS-AD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-02-25; most recent amendment 2023-11-21.
Status change: Recruiting → Active, Not Recruiting 2023-11-21
Status change: Not Yet Recruiting → Recruiting 2022-07-05
Trial Details
NCT Number NCT05270044
Lead Sponsor Pierre Fabre Medicament
Collaborators: European Organisation for Research and Treatment of Cancer - EORTC
Conditions Melanoma
Enrollment 815 participants
Start Date 2022-05-02
Primary Completion 2027-03-31 (estimated)
Study Completion 2035-05-02 (estimated)
Updated on ClinicalTrials.gov 2023-11-22